Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Scilex's profit margin for the twelve months ending Jun 30, 2026 was -1469.8%. For fiscal 2025 it was -1236.4%, against -128.7% the year before. The highest annual figure on record is -61.4% in fiscal 2022.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1236.4% | −1107.8 |
| FY2024 | Dec 31, 2024 | -128.7% | +115.9 |
| FY2023 | Dec 31, 2023 | -244.6% | −183.2 |
| FY2022 | Dec 31, 2022 | -61.4% | +220.9 |
| FY2021 | Dec 31, 2021 | -282.4% | −80.7 |
| FY2020 | Dec 31, 2020 | -201.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1504.7% | −1059.5 |
| Q1 FY2026 | Mar 31, 2026 | -530.0% | −8.8 |
| Q4 FY2025 | Dec 31, 2025 | -961.9% | −918.6 |
| Q3 FY2025 | Sep 30, 2025 | -2441.5% | −2411.1 |
| Q2 FY2025 | Jun 30, 2025 | -445.1% | −215.5 |
| Q1 FY2025 | Mar 31, 2025 | -521.2% | −297.2 |
| Q4 FY2024 | Dec 31, 2024 | -43.4% | +115.6 |
| Q3 FY2024 | Sep 30, 2024 | -30.4% | +320.8 |
| Q2 FY2024 | Jun 30, 2024 | -229.6% | −17.8 |
| Q1 FY2024 | Mar 31, 2024 | -224.0% | +66.6 |
| Q4 FY2023 | Dec 31, 2023 | -159.0% | −8.9 |
| Q3 FY2023 | Sep 30, 2023 | -351.2% | −540.2 |
| Q2 FY2023 | Jun 30, 2023 | -211.8% | +13.3 |
| Q1 FY2023 | Mar 31, 2023 | -290.6% | −156.4 |
| Q4 FY2022 | Dec 31, 2022 | -150.0% | – |
| Q3 FY2022 | Sep 30, 2022 | 189.0% | – |
| Q2 FY2022 | Jun 30, 2022 | -225.1% | – |
| Q1 FY2022 | Mar 31, 2022 | -134.2% | – |